Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 147380
Corporate User License Price USD 6000
Corporate User License Price INR 442140
Site License Price USD 4000
Site License Price INR 294760
Request a Quote

Report Title

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline Review, H1 2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline Review, H1 2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline Review, H1 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline Review, H1 2017



Executive Summary

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD)-Pipeline Review, H1 2017, provides an overview of the Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline landscape.

Peripheral vascular disease (PVD) refers to diseases of the blood vessels (arteries and veins) located outside the heart and brain. Symptoms include painful cramping in hip, thigh or calf muscles after activity, such as walking or climbing stairs (intermittent claudication), leg numbness or weakness, coldness in lower leg or foot, especially when compared with the other side, sores on toes, feet or legs that won't heal, slower growth of toenails and erectile dysfunction in men.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD)-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 1, 3, 12, 7, 10 and 2 respectively.

Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular).

The pipeline guide reviews pipeline therapeutics for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 6

Global Markets Direct Report Coverage 6

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Overview 7

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Products under Development by Companies 12

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Therapeutics Assessment 14

Assessment by Target 14

Assessment by Mechanism of Action 16

Assessment by Route of Administration 18

Assessment by Molecule Type 20

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Companies Involved in Therapeutics Development 22

AnGes MG Inc 22

AstraZeneca Plc 22

Athera Biotechnologies AB 23

Athersys Inc 23

Bayer AG 24

Betagenon AB 24

BiogenCell Ltd 25

CardioVascular BioTherapeutics Inc 25

Celgene Corp 26

Diffusion Pharmaceuticals Inc 26

Foresee Pharmaceuticals LLC 27

Hemostemix Ltd 27

ID Pharma Co Ltd 28

Juventas Therapeutics Inc 28

LipimetiX Development Inc 29

miRagen Therapeutics Inc 29

Novartis AG 30

Nuo Therapeutics Inc 30

Proteon Therapeutics Inc 31

Recardio GmbH 31

Resverlogix Corp 32

Sigma-Tau SpA 32

Stemedica Cell Technologies Inc 33

Theravasc Inc 33

VESSL Therapeutics Ltd 34

ViroMed Co Ltd 34

Yuyu Pharma Inc 35

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Drug Profiles 36

ACP-01-Drug Profile 36

AEM-28-Drug Profile 39

ALD-301-Drug Profile 41

alprostadil-Drug Profile 44

apabetalone-Drug Profile 46

BAY-1193397-Drug Profile 58

beperminogene perplasmid-Drug Profile 59

BGC-101-Drug Profile 64

canakinumab-Drug Profile 65

CVBT-141C-Drug Profile 71

DVC-10101-Drug Profile 72

ELS-140-Drug Profile 73

FP-045-Drug Profile 74

JVS-100-Drug Profile 75

levocarnitine propionate hydrochloride-Drug Profile 80

MRG-110-Drug Profile 81

MultiGeneAngio-Drug Profile 82

MultiGeneGraft-Drug Profile 83

O-304-Drug Profile 84

PC-mAb-Drug Profile 86

PDA-002-Drug Profile 88

PF-05285401-Drug Profile 89

REC-03-Drug Profile 101

Rejuveinix-Drug Profile 102

rivaroxaban-Drug Profile 103

sodium nitrite SR-Drug Profile 119

Stem Cell Therapy for Cardiovascular Disease, Central Nervous System Disorders, Infectious Diseases, Respiratory and Metabolic Disorders-Drug Profile 121

transcrocetinate sodium-Drug Profile 126

TXA-127-Drug Profile 130

TXA-302-Drug Profile 134

V-10-Drug Profile 135

VM-202-Drug Profile 136

vonapanitase-Drug Profile 140

YY-984-Drug Profile 146

zibotentan-Drug Profile 147

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Dormant Projects 149

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Discontinued Products 151

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Product Development Milestones 152

Featured News & Press Releases 152

Appendix 162

Methodology 162

Coverage 162

Secondary Research 162

Primary Research 162

Expert Panel Validation 162

Contact Us 162

Disclaimer 163

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

List of Tables

Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by AnGes MG Inc, H1 2017

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by AstraZeneca Plc, H1 2017

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Athera Biotechnologies AB, H1 2017

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Athersys Inc, H1 2017

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Bayer AG, H1 2017

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Betagenon AB, H1 2017

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by BiogenCell Ltd, H1 2017

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by CardioVascular BioTherapeutics Inc, H1 2017

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Celgene Corp, H1 2017

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Diffusion Pharmaceuticals Inc, H1 2017

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Foresee Pharmaceuticals LLC, H1 2017

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Hemostemix Ltd, H1 2017

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by ID Pharma Co Ltd, H1 2017

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Juventas Therapeutics Inc, H1 2017

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by LipimetiX Development Inc, H1 2017

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by miRagen Therapeutics Inc, H1 2017

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Novartis AG, H1 2017

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Nuo Therapeutics Inc, H1 2017

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Proteon Therapeutics Inc, H1 2017

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Recardio GmbH, H1 2017

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Resverlogix Corp, H1 2017

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Sigma-Tau SpA, H1 2017

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Stemedica Cell Technologies Inc, H1 2017

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Theravasc Inc, H1 2017

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by VESSL Therapeutics Ltd, H1 2017

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by ViroMed Co Ltd, H1 2017

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Yuyu Pharma Inc, H1 2017

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Dormant Projects, H1 2017

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Dormant Projects, H1 2017 (Contd..1), H1 2017

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

AnGes MG Inc, AstraZeneca Plc, Athera Biotechnologies AB, Athersys Inc, Bayer AG, Betagenon AB, BiogenCell Ltd, CardioVascular BioTherapeutics Inc, Celgene Corp, Diffusion Pharmaceuticals Inc, Foresee Pharmaceuticals LLC, Hemostemix Ltd, ID Pharma Co Ltd, Juventas Therapeutics Inc, LipimetiX Development Inc, miRagen Therapeutics Inc, Novartis AG, Nuo Therapeutics Inc, Proteon Therapeutics Inc, Recardio GmbH, Resverlogix Corp, Sigma-Tau SpA, Stemedica Cell Technologies Inc, Theravasc Inc, VESSL Therapeutics Ltd, ViroMed Co Ltd, Yuyu Pharma Inc

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutic Products under Development, Key Players in Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Pipeline Overview, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Pipeline, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand